Spots Global Cancer Trial Database for chronic kidney disease
Every month we try and update this database with for chronic kidney disease cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) | NCT03299244 | Secondary Hyper... Chronic Kidney ... | Etelcalcetide Cinacalcet | 18 Years - | Amgen | |
| Sarcopenia and Risk of Falls in Patients With Major Chronic Diseases | NCT03798418 | Stroke Osteoporosis Chronic Kidney ... Cancer | elastic band st... diet counseling | - | Changhua Christian Hospital | |
| Impact of Lifestyle Modification on the Development of Dementia, Chronic Kidney Disease, Diabetes, Chronic Obstructive Pulmonary Disease, Cancers and Cardiovascular Disease in a Thai General Population | NCT02967406 | Dementia Diabetes Mellit... Chronic Kidney ... Cardiovascular ... Malignancy Chronic Obstruc... | 4 x 4 lifestyle... | 45 Years - 75 Years | Sanpasitthiprasong Hospital | |
| Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D | NCT00977080 | Chronic Kidney ... Secondary Hyper... Hemodialysis | Paricalcitol Cinacalcet | 18 Years - | Abbott | |
| ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism | NCT00135304 | Secondary Hyper... | Sensipar® Vitamin D | 18 Years - | Amgen | |
| Metabolic Changes in Patients With Chronic Cardiopulmonary Disease | NCT02550808 | Heart Failure Chronic Obstruc... Malignancy Chronic Kidney ... | 18 Years - | General and Teaching Hospital Celje | ||
| A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) | NCT04064827 | Chronic Kidney ... Secondary Hyper... | Paricalcitol | 0 Years - 9 Years | AbbVie | |
| Biomarker for Patients With Fabry Disease (BioFabry) | NCT02778295 | Angiokeratomas Chronic Kidney ... Ocular Abnormal... Hearing Loss | 2 Months - | CENTOGENE GmbH Rostock | ||
| Nanshan Elderly Cohort Study | NCT03569735 | Hypertension Type 2 Diabetes... Cardiovascular ... Stroke Obesity Metabolic Syndr... Sarcopenia Chronic Kidney ... Cancer Death | 65 Years - | Sun Yat-sen University | ||
| Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients | NCT01447368 | Kidney Failure Secondary Hyper... Vascular Diseas... | Cinacalcet Surgical total ... | 18 Years - 75 Years | The University of Hong Kong | |
| Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002 | NCT02282813 | Chronic Kidney ... Hyperparathyroi... Vitamin D Defic... | CTAP101 Capsule... Calcitriol Doxercalciferol Paricalcitol | 18 Years - | OPKO Health, Inc. | |
| Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery | NCT02812186 | Cholecystitis Endometriosis Bowel Obstructi... Fibroids Prostate Cancer Chronic Kidney ... Uterine Prolaps... | Deep to Moderat... Moderate to Dee... Rocuronium | 18 Years - | Stony Brook University | |
| Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT) | NCT01219855 | Chronic Kidney ... Secondary Hyper... Vitamin D Insuf... | Cohort 1 CTAP10... Cohort 1 CTAP10... Cohort 1 Matchi... Cohort 2 CTAP10... Cohort 2 Matchi... | 18 Years - 85 Years | OPKO Health, Inc. | |
| Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients | NCT00958451 | Secondary Hyper... Chronic Kidney ... | Paricalcitol Ergocalciferol | 18 Years - | Salem Veterans Affairs Medical Center | |
| Comorbidities and Risk Score in COVID-19 Patients | NCT04670094 | Covid19 | 18 Years - | University of Milano Bicocca | ||
| Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency | NCT01704079 | Chronic Kidney ... Hyperparathyroi... Vitamin D Defic... | CTAP101 30 μg c... Sugar pill to C... | 18 Years - | OPKO Health, Inc. | |
| Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002 | NCT02282813 | Chronic Kidney ... Hyperparathyroi... Vitamin D Defic... | CTAP101 Capsule... Calcitriol Doxercalciferol Paricalcitol | 18 Years - | OPKO Health, Inc. | |
| Treatment of Secondary Hyperparathyroidism in the Uremic Patient | NCT00469599 | Secondary Hyper... Chronic Kidney ... Vitamin D Defic... | paricalcitol alfacalcidol | 18 Years - | Zealand University Hospital | |
| A Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis | NCT03633708 | Secondary Hyper... Chronic Kidney ... | Etelcalcetide | 0 Years - 18 Years | Amgen | |
| A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism | NCT01149291 | Secondary Hyper... End Stage Renal... | 18 Years - | AbbVie | ||
| Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency | NCT01651000 | Chronic Kidney ... Hyperparathyroi... Vitamin D Defic... | CTAP101 30 μg c... Sugar pill to C... | 18 Years - | OPKO Health, Inc. | |
| Optimising Renal Outcome in Myeloma Renal Failure | NCT02424851 | Multiple Myelom... Chronic Kidney ... | Bortezomib Thalidomide Bendamustine Dexamethasone | 18 Years - | Oxford University Hospitals NHS Trust | |
| Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery | NCT02812186 | Cholecystitis Endometriosis Bowel Obstructi... Fibroids Prostate Cancer Chronic Kidney ... Uterine Prolaps... | Deep to Moderat... Moderate to Dee... Rocuronium | 18 Years - | Stony Brook University | |
| Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) | NCT00823303 | Secondary Hyper... Chronic Kidney ... | Paricalcitol Calcitriol | 18 Years - | Washington University School of Medicine | |
| A Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis | NCT03633708 | Secondary Hyper... Chronic Kidney ... | Etelcalcetide | 0 Years - 18 Years | Amgen | |
| ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism | NCT00135304 | Secondary Hyper... | Sensipar® Vitamin D | 18 Years - | Amgen | |
| Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis | NCT01265992 | Secondary Hyper... Chronic Kidney ... | 18 Years - | AbbVie | ||
| Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD) | NCT01479088 | Secondary Hyper... | Cinacalcet HCl | 2 Years - 18 Years | Istituto Giannina Gaslini | |
| Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease | NCT02476526 | Chronic Kidney ... Pulmonary Embol... Renal Artery St... Pulmonary Cance... | Low Volume iso-... Acetylcysteine ... Sodium Bicarbon... 64-MDCT Scannin... | 18 Years - | VA Greater Los Angeles Healthcare System | |
| Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis | NCT01265992 | Secondary Hyper... Chronic Kidney ... | 18 Years - | AbbVie | ||
| Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) | NCT03299244 | Secondary Hyper... Chronic Kidney ... | Etelcalcetide Cinacalcet | 18 Years - | Amgen | |
| Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism | NCT01439867 | Chronic Kidney ... Hyperparathyroi... | Cinacalcet hydr... Standard of Car... | 28 Days - 2189 Days | Amgen | |
| Impact of Lifestyle Modification on the Development of Dementia, Chronic Kidney Disease, Diabetes, Chronic Obstructive Pulmonary Disease, Cancers and Cardiovascular Disease in a Thai General Population | NCT02967406 | Dementia Diabetes Mellit... Chronic Kidney ... Cardiovascular ... Malignancy Chronic Obstruc... | 4 x 4 lifestyle... | 45 Years - 75 Years | Sanpasitthiprasong Hospital | |
| A Natural History Study of Metabolic Sizing in Health and Disease | NCT05398783 | Metabolic Disor... Cancer Chronic Kidney ... Diabetes Normal Physiolo... | 2 Years - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Treatment of Secondary Hyperparathyroidism in the Uremic Patient | NCT00469599 | Secondary Hyper... Chronic Kidney ... Vitamin D Defic... | paricalcitol alfacalcidol | 18 Years - | Zealand University Hospital | |
| Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT) | NCT01224782 | Chronic Kidney ... Secondary Hyper... | 18 Years - | AbbVie | ||
| The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients | NCT00767897 | Chronic Kidney ... Dialysis | Human Papilloma... | 9 Years - 18 Years | Indiana University | |
| Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT) | NCT01219855 | Chronic Kidney ... Secondary Hyper... Vitamin D Insuf... | Cohort 1 CTAP10... Cohort 1 CTAP10... Cohort 1 Matchi... Cohort 2 CTAP10... Cohort 2 Matchi... | 18 Years - 85 Years | OPKO Health, Inc. | |
| Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT) | NCT00792857 | Chronic Kidney ... Secondary Hyper... Chronic Renal I... Chronic Renal F... | CTAP201 Injecti... Doxercalciferol | 18 Years - 80 Years | OPKO Health, Inc. | |
| Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D | NCT00977080 | Chronic Kidney ... Secondary Hyper... Hemodialysis | Paricalcitol Cinacalcet | 18 Years - | Abbott | |
| Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet | NCT01896232 | Secondary Hyper... Chronic Kidney ... | Etelcalcetide Cinacalcet Oral Placebo Intravenous Pla... | 18 Years - 85 Years | Amgen | |
| Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism | NCT01439867 | Chronic Kidney ... Hyperparathyroi... | Cinacalcet hydr... Standard of Car... | 28 Days - 2189 Days | Amgen | |
| A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making | NCT00122135 | Congestive Hear... Chronic Obstruc... Cirrhosis Colon Carcinoma Lung Cancer Chronic Kidney ... | Values Inventor... | 55 Years - | VA Office of Research and Development | |
| Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients | NCT01447368 | Kidney Failure Secondary Hyper... Vascular Diseas... | Cinacalcet Surgical total ... | 18 Years - 75 Years | The University of Hong Kong | |
| Nanshan Elderly Cohort Study | NCT03569735 | Hypertension Type 2 Diabetes... Cardiovascular ... Stroke Obesity Metabolic Syndr... Sarcopenia Chronic Kidney ... Cancer Death | 65 Years - | Sun Yat-sen University | ||
| Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease | NCT01290029 | Chronic Kidney ... Hyperparathyroi... Secondary Hyper... | Cinacalcet | 28 Days - 2190 Days | Amgen | |
| Biomarker for Patients With Fabry Disease (BioFabry) | NCT02778295 | Angiokeratomas Chronic Kidney ... Ocular Abnormal... Hearing Loss | 2 Months - | CENTOGENE GmbH Rostock | ||
| Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers | NCT00097747 | Anemia Chronic Kidney ... Chronic Renal F... Cancer | Placebo peginesatide | 18 Years - 40 Years | Affymax | |
| START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism | NCT00132431 | Kidney Disease Secondary Hyper... Chronic Kidney ... | Sensipar | 18 Years - | Amgen | |
| Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis | NCT00667576 | Chronic Kidney ... Secondary Hyper... | Maxacalcitol Paricalcitol | 20 Years - | Abbott | |
| Pediatric Chronic Kidney Disease Safety and Efficacy | NCT01277510 | Chronic Kidney ... Hyperparathyroi... Hyperparathyroi... Kidney Disease Secondary Hyper... | cinacalcet caps... placebo Standard of Car... | 6 Years - 17 Years | Amgen | |
| Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) | NCT00823303 | Secondary Hyper... Chronic Kidney ... | Paricalcitol Calcitriol | 18 Years - | Washington University School of Medicine | |
| Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease | NCT01290029 | Chronic Kidney ... Hyperparathyroi... Secondary Hyper... | Cinacalcet | 28 Days - 2190 Days | Amgen |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
